NASDAQ: NRSNNeurosense Therapeutics Ltd Stock
$1.35-0.07 (-4.93%)
Updated Apr 22, 2024
NRSN Price
$1.35
Fair Value Price
$0.19
Market Cap
$20.76M
52 Week Low
$0.40
52 Week High
$2.33
P/E
-1.63x
P/B
-11.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.7
Operating Cash Flow
-$8M
Beta
0.59
Next Earnings
May 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NRSN Overview
NeuroSense Therapeutics Ltd. is developing treatment for patients with debilitating neurodegenerative diseases.The company's lead product, PrimeC, is a novel oral formulation in clinical trials to treat amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease, and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics was incorporated in 2017 and is headquartered in Herzliya, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRSN ($1.35) is overvalued by 625.54% relative to our estimate of its Fair Value price of $0.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NRSN ($1.35) is not significantly undervalued (625.54%) relative to our estimate of its Fair Value price of $0.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NRSN due diligence checks available for Premium users.
Be the first to know about important NRSN news, forecast changes, insider trades & much more!
NRSN News
Valuation
NRSN fair value
Fair Value of NRSN stock based on Discounted Cash Flow (DCF)
Price
$1.35
Fair Value
$0.19
Overvalued by
625.54%
NRSN ($1.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NRSN ($1.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NRSN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.63x
Industry
16.21x
Market
41x
NRSN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-11.08x
Industry
5.82x
NRSN's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
NRSN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.2M
Liabilities
$5.1M
Debt to equity
-2.7
NRSN's short-term liabilities ($3.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRSN's short-term assets ($2.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRSN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NRSN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRSN vs Biotech Stocks
Neurosense Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.